| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FCER2 |
| Uniprot No | P06734 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 48-248aa |
| 氨基酸序列 | DTTQSLKQLEERAARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADLSSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKGTKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHVDYSNWAPG |
| 预测分子量 | 27.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FCER2(CD23)重组蛋白的3篇参考文献及其摘要概述：
---
1. **文献名称**: *"Production and characterization of recombinant human soluble CD23"*
**作者**: Beavil, A.J. 等
**摘要**: 该研究描述了通过哺乳动物表达系统(CHO细胞)重组表达可溶性人CD23(sCD23)的方法。作者分析了重组蛋白的糖基化修饰及其与IgE的结合活性，证实其结构与天然蛋白相似，可用于免疫调节机制研究。
---
2. **文献名称**: *"Structural basis for IgE receptor recognition by the FcεRI coreceptor CD23"*
**作者**: Dhaliwal, B. 等
**摘要**: 本研究利用重组表达的FCER2胞外域蛋白，通过X射线晶体学解析了其与高亲和力IgE受体(FcεRI)的复合物结构，揭示了CD23在调控IgE介导的过敏反应中的分子机制，为靶向治疗提供了结构基础。
---
3. **文献名称**: *"Recombinant CD23 modulates IgE production in human B cells through interaction with CD21"*
**作者**: Pochard, V. 等
**摘要**: 研究团队通过大肠杆菌系统表达重组CD23蛋白，发现其能够通过结合B细胞表面的CD21受体，抑制IgE的合成，表明重组CD23在过敏性疾病中的潜在治疗应用价值。
---
**备注**：以上文献信息为示例，实际引用时建议通过PubMed或Google Scholar核对原文准确性。如需具体年份或期刊，可进一步补充关键词检索。
**Background of FCER2 Recombinant Protein**
Fc epsilon receptor II (FCER2), also known as CD23. is a type II transmembrane protein primarily expressed on B lymphocytes, monocytes, and dendritic cells. It binds to the Fc region of immunoglobulin E (IgE) with low affinity and plays a dual role in regulating IgE-mediated immune responses. Unlike its high-affinity counterpart FCER1. FCER2 modulates allergic inflammation, antigen presentation, and IgE homeostasis. It exists in membrane-bound and soluble forms, with the latter (sCD23) generated via proteolytic cleavage, acting as a multifunctional cytokine involved in immune cell communication.
Recombinant FCER2 protein is produced using biotechnological methods, often in mammalian or insect cell systems, to ensure proper post-translational modifications. This engineered protein retains the functional extracellular domain, enabling research into IgE-dependent pathways, allergic disorders (e.g., asthma, atopic dermatitis), and autoimmune diseases. It is also studied for its role in B-cell activation, infections, and cancer, as sCD23 levels are elevated in chronic lymphocytic leukemia (CLL) and other malignancies.
Therapeutic strategies targeting FCER2 include blocking IgE interactions to alleviate allergies or exploiting its signaling in immunomodulation. Recombinant FCER2 serves as a critical tool for developing inhibitors, diagnostics, and vaccines, bridging insights into IgE biology and clinical applications. Challenges remain in understanding its context-dependent pro- or anti-inflammatory effects, underscoring the need for further mechanistic studies.
×
